Testing AS1501 for acute-on-chronic liver failure
Part of Digestive system clinical trials.
This trial tests a new drug called AS1501 for people with acute-on-chronic liver failure (a sudden worsening of chronic liver disease). It aims to see if the drug can help improve liver function and reduce the need for a liver transplant. You may be eligible if you are in the early or middle stage of this condition and have a specific blood marker (high TRAIL level).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with acute-on-chronic liver failure (ACLF) in the early or middle stage, meaning your liver is worsening quickly but you don't yet have severe complications.
- Your blood TRAIL level (a protein marker) must be at least twice the normal level (measured by a blood test).
- You have not had a liver transplant and are not scheduled for one in the next month.
- You do not have an active cancer (like lung, liver, pancreatic, or stomach cancer) based on recent imaging and blood tests.
- You are willing to use effective contraception for up to 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination approach called DPMAS and low-volume plasma exchange for people with hepatitis B–related acute-on-chronic liver failure. If you qualify, the goal is to improve your liver function and reduce serious complications from liver failure.
This Phase 2 trial tests an injection medicine (F573) to see if it can improve people with liver injury, drug-related liver damage, or liver failure. You may be screened with blood tests, liver stiffness measurements, and possibly symptom checks.
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
This study looks at when liver transplant is offered and what outcomes happen in people with cirrhosis who have severe “acute-on-chronic” worsening. It may help doctors decide which patients benefit most from transplant and improve care after listing or not listing.
This trial tests whether infusing stem cells (from a healthy donor) can help people with sudden liver failure that is not getting better with standard medicines and is not caused by viruses. It aims to improve liver function and possibly avoid the need for a transplant.
This study looks at patients with cirrhosis who are admitted to the intensive care unit with acute-on-chronic liver failure. It aims to understand and improve care for this serious condition using a standard scoring system.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.